© copyright 2014 SP, NTU. All Rights Reserved.
No.33, Linsen S. Rd., Zhongzheng Dist., Taipei City 100025,
Taiwan (R.O.C.)
TEL : (02)3366-8750~4 FAX : (02)2391-9098
Web person in charge: Tang-Yih Hsu
Contact Phone : (02)33668743
Latest Update : 2024 / 09 / 30
Privacy & Security Policy
|
|
|
|
|
|
| Ling-Wei HsinTitle:Associate Professor / Director, Center for Innovative Therapeutics Discovery TEL:+886-2-3366-8696 Email:lwhsin@ntu.edu.twNTU SCHOLAR |
Education | : | Ph.D.- Graduate Institute of Pharmaceutical Sciences, College of Medicine, National Taiwan University 1990-1995 B.S.- School of Pharmacy, National Taiwan University 1986-1990 | Experience | : | 2002~ Assistant Professor(School of Pharmacy, College of Medicine, National Taiwan University)
2001-2002 Instructor(School of Pharmacy, College of Medicine, National Taiwan University)
1997-2000 Fogarty Fellow Sponsor: Dr. Kenner C. Rice; Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda, Maryland, USA Design, synthesis, and structure-activity relationships of non-peptide corticotropin-releasing hormone receptor antagonists. The development of chiral derivatives of GBR 12909 and GBR 12935 as potential cocaine abuse therapeutic agents. Synthesis of radiopharmaceuticals as potential PET and SPECT imaging agents.
1995-1997 Pharmaceutical Analysis Scientist The Analytical Center of Medical Supplies National Defense Medical Center Taipei, Taiwan Quantitative and qualitative analyses of prescription drugs and other medical supplies. The development of antidotes for the treatment of neurotoxic agent intoxication. Synthesis of opioid receptor antagonists for pharmacological studies. | Research Areas | : | Drug discovery and development; Medicinal chemistry; Organic synthesis; Pharmaceutical analysis; New radiopharmaceutics | Lab Focus | : | 1. Discovery of early diagnostic agents and personalized precision medicine for Alzheimer's disease 2. New drug development for Irritable Bowel Syndrome 3. Design, synthesis, and application in translational medicine of new drugs for neurodegenerative disease and neuropsychiatric disorders |
|
|
|
|